Medirom Healthcare Partners with World Foundation to Deploy Proof of Human Technology
Medirom Healthcare is collaborating with World Foundation and Tools for Humanity to deploy Proof of Human technologies such as World ID throughout Japan. The World project was co-created by Sam Altman and Alex Blania. In preparation for the full-scale rollout of the World project in Japan, Medirom has entered into a Master Service Agreement with Tools for Humanity and World Foundation. Under the MSA, the Medirom Group will be responsible for the operation of "Proof of Human" verification locations in Japan. This initiative is expected to contribute to MEDIROM's revenue through operation fees and related services over time. Leveraging Medirom's nationwide network of approximately 300 physical locations and operational expertise, the collaboration enables rapid and trusted deployment of Proof of Human technology at scale. To support this effort, Medirom will newly establish a dedicated special task force, the "Medirom World Proof of Human Task Force," and will strengthen its organizational structure to promote the nationwide rollout of Proof of Human technology powered by World.
Trade with 70% Backtested Accuracy
Analyst Views on MRM
About MRM
About the author
Micromem Technologies Closes C$327,778 Private Placement
- Successful Private Placement: Micromem Technologies has closed a non-brokered private placement, raising approximately C$327,778 by issuing 6,555,555 units at C$0.05 each, indicating market confidence in its financing needs.
- Clear Use of Proceeds: The funds raised will be allocated for working capital, reflecting Micromem's strategic intent to enhance its intelligent application development capabilities, particularly in sectors like oil & gas and healthcare.
- Compliance Requirements: The securities issued are subject to post-closing compliance requirements from the Canadian Securities Exchange, ensuring the company operates within legal frameworks and bolstering investor confidence.
- Future Financing Potential: Micromem may close an additional tranche of up to C$167,000 as needed, demonstrating the company's proactive planning for future capital requirements to further support its business growth.
MRM Health Receives FDA Clearance to Initiate MH002 Clinical Trial
- Clinical Trial Launch: MRM Health's MH002 program has received FDA clearance, marking the initiation of the STARFISH-UC Phase 2b clinical trial, which is expected to enroll approximately 204 patients with mild-to-moderate ulcerative colitis, advancing the development of next-generation therapies for inflammatory bowel diseases.
- Efficacy Validation: MH002 demonstrated excellent safety and encouraging efficacy in its Phase 2a trial, with significant mucosal healing and anti-inflammatory effects observed after 8 weeks of treatment, laying a solid foundation for the upcoming Phase 2b trial.
- Innovative Technology Platform: MH002 is designed and manufactured using MRM Health's CORAL® platform, ensuring drug consistency and high quality, which supports cost-effective treatments for chronic inflammatory conditions and holds significant market potential.
- Funding Support: MRM Health successfully closed a €55 million Series B round in September 2025, enhancing its R&D capabilities in inflammatory diseases and providing financial backing for future clinical advancements.
